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Abstract
Interfering with bacterial cell-to-cell communication is a promising strategy to combat antimicrobial resistance. The natural prod-
uct hamamelitannin and several of its analogues have been identified as quorum sensing inhibitors. In this paper the synthesis of
pyrrolidine-based analogues of a more lead-like hamamelitannin analogue is reported. A convergent synthetic route based on a key
ring-closing metathesis reaction was developed and delivered the pyrrolidine analogue in 17 steps in high yield. Chemoselective
derivatization of the pyrrolidine nitrogen atom resulted in 6 more compounds. The synthesized compounds were evaluated in a
biofilm model, but were all inactive.
Introduction
Antimicrobial resistance is rapidly becoming a global threat
[1,2]. It is estimated that worldwide, at least 700 000 people die
every year from drug-resistant strains of common bacterial
infections. Strategies to deal with the global antimicrobial resis-
tance problem need to be multifactorial. Next to disease preven-
tion and the development of new antibiotics, it is essential to in-
vestigate innovative strategies to combat bacterial infections
[3,4]. Recently, targeting bacterial virulence has gained a lot of
attention [5-7]. It has been hypothesized that by “disarming” the
pathogen, rather than inhibiting its growth, selective pressure
for resistance development will be much lower. Furthermore,
reduction of bacterial virulence directly protects the host, and at
the same time renders the bacteria more susceptible towards the
host defense system and antibiotics.
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Figure 1: Structures of hamamelitannin (1), lead compound 2 and target compounds 3.
The Centers for Disease Control and Prevention (CDC) have
listed a number of bacteria that present serious, urgent and con-
cerning threats [8]. One of these problematic bacteria is methi-
cillin-resistant Staphylococcus aureus (MRSA), a human
pathogen that causes a wide range of clinical infections. In
S. aureus, virulence is mainly mediated by quorum sensing, a
bacterial cell-to-cell communication system based on the secre-
tion of signal molecules [9-11]. The natural product hamameli-
tannin (1) has been identified as a non-peptide analogue of RIP
(RNAIII-inhibiting protein), an inhibitor of the RAP/TRAP
(RNAIII-activating protein/target of RAP) quorum sensing
system in S. aureus (Figure 1) [12-14]. Furthermore, hamameli-
tannin has been shown to inhibit biofilm formation and to
potentiate the activity of antibiotics against staphylococcal
biofilms in vitro and in vivo [12,15]. Structural optimization of
hamamelitannin by our group resulted in several more potent
and more druglike analogues of which compound 2 emerged as
a promising starting point for further optimization and subse-
quent development (Figure 1) [16-19]. Our earlier work
revealed that the optimal side chain substituents are an
o-chlorobenzamide on the 5-position and a non-substituted
benzamide on the 2’-position. In absence of any structural infor-
mation of the inhibitor–target interaction, we were interested in
replacing the core tetrahydrofuran scaffold by a pyrrolidine ring
in order to further elucidate the structure–activity relationship.
The pyrrolidine nitrogen atom provides an extra point of diver-
sification, allowing further elaboration of the scaffold. Substitu-
ents on the ring nitrogen might lead to additional interactions
with the target and therefore provide more potent analogues.
Moreover, the O-to-N replacement is expected to increase solu-
bility and possible polar interactions with the target. In this
work we report the design, synthesis and biological evaluation
of a number of pyrrolidine-based hamamelitannin analogues.
The envisioned strategy for the synthesis of the target pyrrol-
idine-based hamamelitannin analogues is depicted in Scheme 1.
The synthesis of 4 as a key intermediate allows to gain access to
a diverse set of analogues by chemoselective late-stage derivati-
zation of the pyrrolidine nitrogen. Previously, we used the
iminosugar 5 to prepare a series of 2’-homoazanucleosides.
This possible precursor was synthesized convergently in
12 steps [20]. The pyrrolidine ring was constructed via alkyl-
ation of 6 and 7, followed by ring-closing metathesis. Stereose-
lective dihydroxylation of the resulting alkene then furnished
the protected iminosugar 5. However, using intermediate 5 as a
starting point for the hamamelitannin analogues would render
the synthetic route very linear and impractical to produce suffi-
cient amounts required to prepare a series of analogues.
Therefore, we envisioned a modification of the previously de-
veloped synthetic route, where the two fully functionalized side
chains are introduced prior to coupling and ring closure to
afford 8. This new synthetic route would be more convergent
and efficient for the preparation of 3. Retrosynthetic analysis
led to 9 and 10 as two key synthons, which would be assem-
bled via a Mitsunobu–Fukuyama reaction, and subsequently the
secondary amine converted to the pyrrolidine ring via a ring-
closing metathesis reaction [21].
Results and Discussion
Chemistry
The synthesis of fragment 9 is depicted in Scheme 2 and proved
to be challenging. It was essential to introduce the nosyl group
only in the last step, since several previous attempts to synthe-
size 9 failed due to side reactions caused by the strongly elec-
tron-withdrawing properties of the nosyl group. The successful
synthesis starts with a Pd-catalyzed dynamic kinetic asym-
metric transformation of racemic butadiene monoepoxide to 12,
employing phthalimide as nucleophile [22,23]. Attempts to
substitute the alcohol functionality of 12 via displacement of the
derived mesylate with NaN3 failed, similar to previously re-
ported difficulties by Trost et al. [24]. The benzamide substitu-
ent was therefore introduced via Mitsunobu reaction with
N-Boc-protected ortho-chlorobenzamide 13. Removal of the
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Scheme 1: Proposed strategy for the synthesis of the target analogues.
Scheme 2: Synthesis of fragment 9. Reagents and conditions: a) phthalimide, Pd2(allyl)2Cl2, ligand 15, Na2CO3, CH2Cl2, rt; b) i) 13, DEAD, PPh3,
toluene, 0 °C to rt; ii) TFA, CH2Cl2, H2O, rt; c) i) ethylenediamine, EtOH/THF 7:3, reflux; ii) p-Ns-Cl, Et3N, THF, 0 °C.
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Scheme 4: Coupling of 9 and 10 and attempted ring-closing metathesis. Reagents and conditions: a) PPh3, DEAD, THF/DMF 2:1, 0 °C to rt;
b) 5 mol % Grubbs–Hoveyda II, 1,2-DCE, 50 °C.
Boc-group with TFA resulted in 14. Next, the phthalimide was
removed via refluxing with ethylenediamine and the resulting
amine protected as para-nitrobenzenesulfonamide to obtain the
desired fragment 9.
The synthesis of 10 starts from commercially available 2-meth-
ylene-1,3-propanediol (16), which was selectively monopro-
tected in high yield as TBS ether (Scheme 3) [25]. The
remaining alcohol was then substituted for a phthalimide via
Mitsunobu reaction. Phthalimide deprotection, acylation with
benzoic acid, and removal of the silyl protecting group
furnished 10.
Fragments 9 and 10 were coupled under Mitsunobu conditions
(Scheme 4), affording 20 contaminated with Mitsunobu byprod-
ucts. Unfortunately, attempted ring-closing metathesis of 20
using the Grubbs–Hoveyda II catalyst failed to produce any
product, probably due to the insolubility of 20 in solvents suit-
able for metathesis reactions (1,2-DCE, toluene) and/or the
coordinating ability of the three (sulfon)amide functionalities
[26,27].
To circumvent this problem, we were forced to alter the initial
synthetic strategy and used a different eastern fragment for the
ring-closing metathesis reaction. The ortho-chlorobenzamide
substituent would then be introduced in a later stage. We chose
to protect alcohol 12 as TBS ether and used the derived nosyl-
protected fragment 23 as the coupling partner (Scheme 5).
Fragments 23 and 10 were coupled via Mitsunobu reaction,
yielding 24 in 49% yield (Scheme 6). Fortunately, ring-closing
metathesis of 24 now smoothly afforded 25 in high yield.
Scheme 3: Synthesis of fragment 10. Reagents and conditions:
a) TBSCl, NaH, THF, rt; b) phthalimide, PPh3, DEAD, THF, 0 °C to rt;
c) H2NNH2·H2O, MeOH, reflux; d) BzCl, Et3N, CH2Cl2, 0 °C; e) TBAF,
THF, rt.
Dihydroxylation selectively yielded the desired stereoisomer of
diol 26, which was subsequently protected as isopropylidene
acetal. In the next step, after removal of the TBS group and
mesylation, attempted substitution with NaN3 resulted only in
an elimination product. This led us to replace the electron-with-
drawing nosyl protecting group with a Boc group. After
removal of the TBS ether and mesylation of the resulting
alcohol, substitution with NaN3 now smoothly provided azide
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Scheme 6: Synthesis of 4. Reagents and conditions: a) PPh3, DEAD, THF, 0 °C to rt; b) Grubbs–Hoveyda II (5 mol %), 1,2-DCE, 50 °C;
c) K2OsO4·2H2O, NMO, acetone/H2O 3:1, rt; d) 2-methoxypropene, CSA (cat.), THF, rt; e) PhSH, K2CO3, MeCN, 50 °C; f) Boc2O, Et3N, CH2Cl2, rt;
g) TBAF, THF, rt; h) Ms-Cl, Et3N, CH2Cl2, 0 °C; i) NaN3, DMF, 60 °C; j) PMe3, H2O, THF, rt; k) 2-chlorobenzoyl chloride, Et3N, CH2Cl2, 0 °C;
l) conc. HCl, MeOH/H2O 1:1, reflux.
Scheme 5: Synthesis of alternative eastern fragment 23. Reagents
and conditions: a) TBSCl, imidazole, CH2Cl2, rt; b) H2NNH2·H2O,
MeOH, reflux; c) p-Ns-Cl, Et3N, CH2Cl2, 0 °C.
29. The azide was then reduced under classical Staudinger
conditions, followed by amide formation with ortho-chloroben-
zoic acid and a final acidic deprotection step to provide the
desired analogue 4. Despite the change of the initial strategy
and resulting elongation of the synthetic route, the overall syn-
thesis still proved to be very efficient, delivering 4 in 6% yield
in 17 steps from 16.
The pyrrolidine nitrogen was then further derivatized with
several small substituents (Scheme 7). Reductive amination
with several aldehydes resulted in 3a–c. The N-methyl ana-
logue 3d was synthesized via methylation with MeI. The
methanesulfonamide 3e and acetamide 3f, in which the cationic
character of the pyrrolidine nitrogen is removed, were also syn-
thesized.
The correct stereochemistry of the synthesized analogues was
unequivocally proven via X-ray structural analysis of com-
pound 3a (Figure 2).
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Scheme 7: Late stage functionalization of the pyrrolidine nitrogen. Reagents and conditions: A) (masked) aldehyde, NaBH3CN, AcOH, MeOH, 60 °C;
B) MeI, DIPEA, THF, 0 °C; C) Ms-Cl, Et3N, THF, 0 °C; D) AcOH, DIPEA, HATU, DMF, rt.
Figure 2: Molecular X-ray structure of 3a, showing thermal displace-
ment ellipsoids at the 50% probability level. Positional disorder of the
chlorophenyl ring and the water solvent molecule are not shown.
Biological evaluation
The synthesized analogues were tested in a S. aureus biofilm
model, but were all inactive (see Supporting Information
File 1).
Conclusion
A convergent synthetic route for the synthesis of pyrrolidine-
based hamamelitannin analogues was developed. The origi-
nally envisioned strategy failed due to difficulties in the ring-
closing metathesis reaction, but modification of one of the cou-
pling partners solved this issue. The desired pyrrolidine-based
analogue was synthesized in 17 steps and chemoselective modi-
fication of the nitrogen atom provided 6 analogues. Unfortu-
nately, these analogues were inactive in inhibiting S. aureus
biofilm formation.
Supporting Information
Supporting Information File 1
Experimental details.
[https://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-14-260-S1.pdf]
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